U.S. midterms dampen Big Pharma hopes for drug price policy change - RawStory.com | Agents of Behemoth | Scoop.it

WASHINGTON (Reuters) - The divided U.S. Congress after the November midterm elections undermines pharmaceutical companies who want to weaken a new law that allows the government to negotiate drug prices, Republican strategists, policy experts and pharmaceutical executives say